Italian VC house Principia has led a €10m series-A funding round for Milan-based startup CheckMab, which specialises in developing a monoclonal antibody for cancer immunotherapy.
Managing director Craig Ferguson discusses accelerated deployment activity during the pandemic and plans to scale up the PE allocation by 2025
Fund has a target of $600m, which it plans to reach by next year, according to Kommersant
Existing investors including Institut Català de Finances also take part in the financing
Biotech company initially raised €12m in December 2018